# Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma

> **NCT02559791** · PHASE2,PHASE3 · COMPLETED · sponsor: **McMaster University** · enrollment: 10 (actual)

## Conditions studied

- Severe Persistent Asthma
- Eosinophilic Bronchitis

## Interventions

- **BIOLOGICAL:** Reslizumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02559791
- **Lead sponsor:** McMaster University
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10
- **Primary completion:** 2017-04
- **Final completion:** 2017-08
- **Target enrollment:** 10 (ACTUAL)
- **Last updated:** 2018-04-04

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02559791

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02559791, "Anti-Interleukin-5 (IL5) Monoclonal Antibody (MAb) in Prednisone-dependent Eosinophilic Asthma". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02559791. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*